Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

532 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Somatic 9p24.1 alterations in HPV- head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity.
Zhao X, Cohen EEW, William WN Jr, Bianchi JJ, Abraham JP, Magee D, Spetzler DB, Gutkind JS, Alexandrov LB, Cavenee WK, Lippman SM, Davoli T. Zhao X, et al. Among authors: gutkind js. Proc Natl Acad Sci U S A. 2022 Nov 22;119(47):e2213835119. doi: 10.1073/pnas.2213835119. Epub 2022 Nov 17. Proc Natl Acad Sci U S A. 2022. PMID: 36395141 Free PMC article.
Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.
Madera D, Vitale-Cross L, Martin D, Schneider A, Molinolo AA, Gangane N, Carey TE, McHugh JB, Komarck CM, Walline HM, William WN Jr, Seethala RR, Ferris RL, Gutkind JS. Madera D, et al. Among authors: gutkind js. Cancer Prev Res (Phila). 2015 Mar;8(3):197-207. doi: 10.1158/1940-6207.CAPR-14-0348. Epub 2015 Feb 13. Cancer Prev Res (Phila). 2015. PMID: 25681087 Free PMC article.
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.
William WN Jr, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman SM. William WN Jr, et al. Among authors: gutkind js. JAMA Oncol. 2016 Feb;2(2):209-16. doi: 10.1001/jamaoncol.2015.4364. JAMA Oncol. 2016. PMID: 26540028 Free PMC article. Clinical Trial.
Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer.
Carter H, Marty R, Hofree M, Gross AM, Jensen J, Fisch KM, Wu X, DeBoever C, Van Nostrand EL, Song Y, Wheeler E, Kreisberg JF, Lippman SM, Yeo GW, Gutkind JS, Ideker T. Carter H, et al. Among authors: gutkind js. Cancer Discov. 2017 Apr;7(4):410-423. doi: 10.1158/2159-8290.CD-16-1045. Epub 2017 Feb 10. Cancer Discov. 2017. PMID: 28188128 Free PMC article.
mTOR co-targeting strategies for head and neck cancer therapy.
Wang Z, Valera JC, Zhao X, Chen Q, Gutkind JS. Wang Z, et al. Among authors: gutkind js. Cancer Metastasis Rev. 2017 Sep;36(3):491-502. doi: 10.1007/s10555-017-9688-7. Cancer Metastasis Rev. 2017. PMID: 28822012 Free PMC article. Review.
The Next Frontier: Head and Neck Cancer Immunoprevention.
Gutkind JS, Bui JD. Gutkind JS, et al. Cancer Prev Res (Phila). 2017 Dec;10(12):681-683. doi: 10.1158/1940-6207.CAPR-17-0331. Epub 2017 Nov 14. Cancer Prev Res (Phila). 2017. PMID: 29138137 Free PMC article.
532 results